1、novotech-Global Clinical Trial LandscapeJULY 25,2023Gallbladder Cancer Gallbladder cancer(GBC)develops when malignant(cancer)cells proliferate in the gallbladder.GBC develops in the mucosal layer(the innermost layer of your gallbladder)and spreads outward.According to studies,GBC is the most frequen

2、t biliary tract cancer,accounting for 80%-95%of all biliary tract cancer globally.It is the sixth most common kind of gastrointestinal cancer.APAC contributed 50%of GBC trials,led by Mainland China and South Korea.The US and Europe conducted 40%of GBC trials,with the United States being dominant in

3、North America,while the United Kingdom,leads in Europe.Over the past five years,venture funding for GBC drug research and development has been volatile,showing fluctuations in deal volumes and values annually.The top biotech and pharma companies that received funding for GBC are Nanjing Transthera B

4、iosciences and Jinfang Pharma.GBC is more common in women than in men.Globally,GBC accounted for more than 1 million new cases.Asia record-ed the highest incidence and mortali-ty cases accounting for 70%of global occurrences.GBC is rare in Europe and the US,comprising around 10%and 4%of global cases

5、 in 2020.70%10%1M50%Small molecules are the most common molecule type under development across multiple phases for GBC,indicating their significance in potential treatments for this cancer type.Monoclonal Antibodies,Antibody-Drug Conjugates,Synthetic Peptides,and Fusion Proteins are emerging drug cl

6、asses for the treatment of GBC.GALLBLADDER CANCER(GBC)GLOBAL CLINICAL TRIAL LANDSCAPEThe content of this publication is proprietary to Novotech Health Holdings.No part of this publication may be reproduced,distributed,or transmitted in any form or by any means,including photocopying,recording,or oth